BOULDER, Colo. - Edgewise Therapeutics Inc. (NASDAQ:EWTX), a biopharmaceutical company focused on muscle disease treatment ...

Edgewise Therapeutics , Inc., a biotechnology company specializing in pharmaceutical preparations, announced the promotion of ...

Edgewise Therapeutics (EWTX) stock traded flat as Stifel launched its coverage with a Hold recommendation, indicating a ...

Paul Matteis, an analyst from Stifel Nicolaus, has initiated a new Hold rating on Edgewise Therapeutics (EWTX).Invest with Confidence: Follow ...

Edgewise Therapeutics (EWTX) announced changes to its executive team. These changes include the addition of Robert Blaustein, joining the ...

Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Get Free Report) was the target of a significant growth in short interest during ...

Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided recent ...

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders ...

--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive topline results from the Phase 2 CANYON trial of ...

Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease Edgewise Therapeutics reports promising Phase 2 results for sevasemten ...

So notwithstanding the buoyant share price, we think it's well worth asking whether Edgewise Therapeutics' cash burn is too risky. In this report, we will consider the company's annual negative free ...

BOULDER, Colo., January 13, 2025--Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided recent corporate updates and highlighted upcoming ...